Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	893.37	435.45	121.63	172.15	200.83
Short-Term Investments	217.19	206.82	1.47	83.87	175.75
Cash & Short-Term Investments	1,111	642.27	123.1	256.01	376.57
Cash Growth	72.91%	421.75%	-51.92%	-32.02%	9.05%
Other Current Assets	16.03	17.01	6.28	9.58	5.82
Total Current Assets	1,127	659.28	129.38	265.59	382.39
Net Property, Plant & Equipment	44.77	30.01	33.39	38.41	40.96
Other Long-Term Assets	15.6	1.94	2.32	2.32	2.31
Total Assets	1,187	691.23	165.08	306.33	425.66
Accounts Payable	8.08	6.56	22.94	5.26	4.03
Accrued Expenses	37.55	30.85	23.44	18.22	20.8
Current Portion of Leases	5	4.85	4.72	4.61	3.89
Total Current Liabilities	50.63	42.26	51.1	28.09	28.72
Long-Term Debt	148.92	-	-	-	-
Long-Term Leases	15.28	19.14	22.7	25.87	28.74
Total Long-Term Liabilities	164.2	19.14	22.7	25.87	28.74
Total Liabilities	214.83	61.4	73.79	53.96	57.47
Common Stock	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	2,368	1,580	723.8	649.5	596.93
Accumulated Other Comprehensive Income	0.48	0.01	-	-0.57	-0.27
Retained Earnings	-1,396	-949.93	-632.51	-396.57	-228.47
Shareholders' Equity	972.13	629.84	91.29	252.36	368.2
Total Liabilities & Equity	1,187	691.23	165.08	306.33	425.66
Total Debt	169.2	23.99	27.42	30.48	32.64
Net Cash (Debt)	941.36	618.28	95.69	225.53	343.94
Net Cash Growth	52.25%	546.16%	-57.57%	-34.43%	-0.40%
Net Cash Per Share	7.33	6.57	1.60	4.34	6.76
Book Value	972.13	629.84	91.29	252.36	368.2
Book Value Per Share	7.57	6.69	1.53	4.86	7.23
Tangible Book Value	972.13	629.84	91.29	252.36	368.2
Tangible Book Value Per Share	7.57	6.69	1.53	4.86	7.23

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q